

Applicants: Ng et al.  
U.S.S.N.: 08/670,119  
Filed: June 25, 1996  
Page 3

FAX RECEIVED

JAN 26 1999

GROUP 1600

D<sup>3</sup> 32. (Amended) The method of claim 30 wherein the disorder is [hypertension or] cardiac arrhythmia.

D<sup>4</sup> 35. (Amended) The method of claim 33 wherein the disorder is hypertension [or cardiac arrhythmia].

D<sup>5</sup> 36. (Twice Amended) The method of claim 18 wherein the integral membrane protein has a plurality of transmembrane domains and wherein the antagonist peptide [comprises] consists essentially of at least four consecutive amino acid residues from the amino acid sequence of any one of said plurality of transmembrane domains or a conservative amino acid substitution variant of said peptide.

62. (Amended) The method of claim [60] 22 wherein the [tyrosine kinase receptor] integral membrane protein is a channel protein.

)<sup>6</sup> 63. (Amended) The method of claim [60] 22 wherein the [tyrosine kinase receptor] integral membrane protein is a T cell antigen receptor.

64. (Amended) The method of claim [60] 22 wherein the [tyrosine kinase receptor] integral membrane protein is a transporter protein.

## REMARKS

Claims 18, 20-37, and 60-65 are pending in the application. Claims 18, 32, 35, 36, and 62-64 are amended herein. The Specification is amended to correct typographical and formatting errors. Applicants submit that no new matter is added by any of the amendments.